Additional file 2 of Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

Supplementary Material 2: Table S1. Acronym and Full Name. Table S2. SgRNA Sequences of Genes in the CDTSL Library. Table S3. MAGeCK negative P-values for Day 14 CDTSL vs. Day 0, Day 14 CDTSL(+Met) vs. Day 0, Day 14 CDTSL(+Met) vs. Day 14 CDTSL, and the list of 67 metformin-sensitizing genes identified through the three-step screening strategy. Table S4. RNA-seq counts for SAHA vs Ctrl, Metformin vs Ctrl, and Combination vs SAHA. Table S5. Differential analysis results of SAHA vs Control. Table S6. Differential analysis results of Metformin vs Control. Table S7. Differential analysis results of SAHA combined with Metformin vs SAHA alone. Table S8. List of Primers Used for ChIP-qPCR, qPCR, Overexpression, and siRNA Experiments. Table S9. CMap analysis of the gene expression profile in metformin-treated cells assessed whether SAHA (Vorinostat) is a highly sensitive drug after metformin treatment. Table S10. 129 intersection genes between upregulated genes after SAHA treatment and downregulated genes after Metformin treatment.